Hims & Hers Launches AI Service to Help Providers Personalize Treatments

YouTube video

What You Should Know: 

Hims & Hers Health, the leading health and wellness platform, has unveiled MedMatch, an AI-powered solution designed to revolutionize healthcare by providing providers with a more intelligent and informed way to deliver personalized care to patients, offering more effective and precise treatments and medications.

– The goal of MedMatch is to recommend clinical decisions and treatments informed by the collective knowledge of thousands of providers and millions of data points, ultimately leading to better clinical outcomes and patient satisfaction.

AI-Powered Personalized Treatments

The United States is facing a mental health crisis, with stigma, lack of education, and a shortage of mental health professionals creating a significant gap in access to treatment. Traditional treatment often involves multiple visits, time, and financial burdens, and it’s typically based on a single provider’s experience. To resolve this, MedMatch aims to assist providers in identifying the optimal treatment for each patient, including the most suitable treatment formulation, dosage strength, and form factor. It is trained on anonymized historical clinical data, demographics, treatment types, and patient outcomes.

MedMatch is initially deployed for customers seeking support for anxiety and depression on the Hims & Hers platform. The platform is currently in Beta and utilizes artificial intelligence and machine learning. It leverages an extensive dataset from the Hims & Hers platform, incorporating millions of anonymized data points from millions of customers.

Future Expansion and Development

As MedMatch’s development continues, the plan is to enhance its capabilities and expand it to cover additional health categories on the Hims & Hers platform. The goal is to provide personalized care to patients across various healthcare conditions. Hims & Hers promises further developments and updates on MedMatch in the coming months.

A crack of light for Pfizer

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox.  Morning. Today, we are sad

Read More »